CLINICAL_TRIALS
trial_result
· 2020-02-21
Clinical Trial Update: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine [Phase 2]
Summary
Phase 2 study of galcanezumab (LY2951742) in Japanese participants with episodic migraine completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2020-02-21